Myeloperoxidase and free iron levels: Potential biomarkers for early detection and prognosis of ovarian cancer

Cancer Biomarkers

Volumn 10, Issue 6, 2011, Pages 267-275

  Fletcher, Nicole M ^a   Jiang, Zhongliang ^a   Ali Fehmi, Rouba ^a   Levin, Nancy K ^b   Belotte, Jimmy ^a   Tainsky, Michael A ^b   Diamond, Michael P ^a   Abu Soud, Husam M ^a   Saed, Ghassan M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

biomarkers; free iron; Myeloperoxidase; ovarian cancer

Indexed keywords

BIOLOGICAL MARKER; IRON; MYELOPEROXIDASE;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IRON BLOOD LEVEL; OVARY CANCER; OVARY INFLAMMATION; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IRON; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PEROXIDASE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864445472     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2012-0255     Document Type: Article

References (50)

1. Jemal, A., et al., Cancer statistics, 2006. CA Cancer J Clin, 2006. 56(2): Pp. 106-30.
2. Leahy, Y., Are serum protein biomarkers effective in Detecting ovarian cancer in its early stages? Clin J Oncol Nurs, 2009. 13(4): Pp. 443-5.
3. Screening for ovarian cancer: Recommendation statement U.S. Preventive Services Task Force. Am Fam Physician, 2005. 71(4): Pp. 759-62.
4. Balkwill, F. and A.Mantovani, Inflammation and cancer: back to Virchow? Lancet, 2001. 357(9255): Pp. 539-45.
5. Ness, R.B. and C. Cottreau, Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst, 1999. 91(17): Pp. 1459-67.
6. Markiewski, M.M., et al., Modulation of the antitumor immune response by complement. Nat Immunol, 2008. 9(11): pp. 1225-35.
7. Rosin, M.P., Anwar, W.A. and A.J.Ward, Inflammation, chromosomal instability, and cancer: The schistosomiasis model. Cancer Res, 1994. 54(7 Suppl): Pp. 1929s-1933s.
8. Podrez, E.A., et al., Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest, 1999. 103(11): Pp. 1547-60.
9. Kensler, T.W., et al., Role of inflammatory cells in themetabolic activation of polycyclic aromatic hydrocarbons in mouse skin. Toxicol Appl Pharmacol, 1987. 90(2): Pp. 337-46.
10. Saed, G.M., et al., Myeloperoxidase serves as a redox switch that regulates apoptosis in epithelial ovarian cancer. Gynecol Oncol, 2010. 116(2): Pp. 276-81.
11. Galijasevic, S., et al.,Myeloperoxidase interactionwith peroxynitrite: Chloride Deficiency and heme Depletion. Free Radic Biol Med, 2009. 47(4): Pp. 431-9.
12. Maitra, D., et al.,Melatonin canmediate its vascular protective effect bymodulating free iron level by inhibiting hypochlorous acid-mediated hemoprotein heme Destruction. Hypertension, 2011. 57(5): P. e22; author reply e23.
13. Maitra, D., et al., Reaction of hemoglobin with HOCl: Mechanism of heme Destruction and free iron release. Free Radic Biol Med, 2011. 51(2): Pp. 374-86.
14. Maitra, D., et al., Mechanism of hypochlorous acid-mediated heme Destruction and free iron release. Free Radic Biol Med, 2011. 51(2): Pp. 364-73.
15. Muscara, M.N., et al., Wound collagen Deposition in rats: Effects of an NO-NSAID and a selective COX-2 inhibitor. Br J Pharmacol, 2000. 129(4): Pp. 681-6.
16. Shi, H.P., et al., The role of iNOS in wound healing. Surgery, 2001. 130(2): Pp. 225-9.
17. Witte, M.B. and A. Barbul, Role of nitric oxide in wound repair. Am J Surg, 2002. 183(4): Pp. 406-12.
18. Sadrzadeh, S.M., et al., Hemoglobin. A biologic fenton reagent. J Biol Chem, 1984. 259(23): Pp. 14354-6.
19. Sasaroli, D., Coukos, G. and N. Scholler, Beyond CA125: The coming of age of ovarian cancer biomarkers. Are we there yet? Biomark Med, 2009. 3(3): Pp. 275-288.
20. Schummer, M., et al., Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene, 1999. 238(2): Pp. 375-85.
21. Drapkin, R., et al., Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res, 2005. 65(6): p. 2162-9.
22. Gilks, C.B., et al., Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol, 2005. 96(3): pp. 684-94.
23. Hough, C.D., et al., Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res, 2000. 60(22): Pp. 6281-7.
24. Galgano, M.T., Hampton, G.M. and H.F. Frierson, Jr., Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol, 2006. 19(6): Pp. 847-53.
25. Bouchard, D., et al., Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol, 2006. 7(2): Pp. 167-74.
26. Rosen, D.G., et al., Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol, 2005. 99(2): Pp. 267-77.
27. Scholler, N., et al., Bead-based ELISA for validation of ovarian cancer early Detection markers. Clin Cancer Res, 2006. 12(7 Pt 1): Pp. 2117-24.
28. Moore, R.G., et al., The use of multiple novel tumor biomarkers for the Detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol, 2008. 108(2): Pp. 402-8.
29. Kim, J.H., et al., Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA, 2002. 287(13): Pp. 1671-9.
30. Menon, U., et al., Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol, 2005. 23(31): Pp. 7919-26.
31. Xu, F., et al., OVX1 as a marker for early stage endometrial carcinoma. Cancer, 1994. 73(1): Pp. 1855-8.
32. Havrilesky, L.J., et al., Evaluation of biomarker panels for early stage ovarian cancer Detection andmonitoring for disease recurrence. Gynecol Oncol, 2008. 110(3): Pp. 374-82.
33. Loria, V., et al., Myeloperoxidase: A new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm, 2008. 2008: P. 135625.
34. Dally, H., et al., Myeloperoxidase (MPO) genotype and lung cancer histologic types: The MPO -463 A allele is associated with reduced risk for small cell lung cancer in smokers. Int J Cancer, 2002. 102(5): Pp. 530-5.
35. Piedrafita, F.J., et al., An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormoneretinoic acid response element. J Biol Chem, 1996. 271(24): pp. 14412-20.
36. Heinecke, J.W., et al., Tyrosyl radical generated by myeloper oxidase catalyzes the oxidative cross-linking of proteins. J Clin Invest, 1993. 91(6): Pp. 2866-72.
37. Osterreicher, C.H., et al., Association ofmyeloperoxidase promotor polymorphism with cirrhosis in patients with hereditary hemochromatosis. J Hepatol, 2005. 42(6): Pp. 914-9.
38. Choi, J.Y., et al., Iron intake, oxidative stress-related genes MnSOD and MPO) and prostate cancer risk in CARET cohort. Carcinogenesis, 2008. 29(5): Pp. 964-70.
39. Ekmekci, O.B., et al., Iron, nitric oxide, and myeloperoxidase in asthmatic patients. Biochemistry (Mosc), 2004. 69(4): pp. 462-7.
40. Serum Iron. Serum Iron 2006; Available from: http://uimc. discoveryhospital.com/main.php?id=1456.
41. Medline, Serum Iron. Serum Iron 2010; Available from: http:// www.nlm.nih.gov/medlineplus/ency/article/003488.htm.
42. Brennan, M.L., et al., Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med, 2003. 349(17): pp. 1595-604.
43. Baldus, S., et al., Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation, 2003. 108(12): Pp. 1440-5.
44. Bozzini, C., et al., Biochemical and genetic markers of iron status and the risk of coronary artery disease: An angiographybased study. Clin Chem, 2002. 48(4): Pp. 622-8.
45. De Valk, B. and J.J. Marx, Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med, 1999. 159(14): Pp. 1542-8.
46. Sullivan, J.L., Iron and the genetics of cardiovascular disease. Circulation, 1999. 100(12): Pp. 1260-3.
47. Niederau, C., Iron overload and atherosclerosis. Hepatology, 2000. 32(3): Pp. 672-4.
48. Zhu, C.S., et al., A framework for evaluating biomarkers for early Detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila), 2011. 4(3): Pp. 375-83.
49. Baker, S.G., et al., Evaluating markers for the early Detection of cancer: Overview of study Designs andmethods. Clin Trials, 2006. 3(1): Pp. 43-56.
50. Skates, S.J., et al., Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer, 1995. 76(10 Suppl): Pp. 2004-10.